Organos

Cardiac disease remains the leading cause of death. Despite the need for new cardiac therapies to address this, new pharmaceutical treatments stagnate. The challenge is the lack of predictive human-relevant preclinical models of the human heart that are amenable to high-throughput screening (HTS) assays. Despite intense R&D productivity, large compound libraries remain virtually unexplored in a predictive cardiac tissue model, hindering discovery of novel therapeutic approaches to treat heart disease.